PDCD1 and small cell lung carcinoma: Meanwhile, the recent ASTRUM-005 study showed that first-line treatment with chemotherapy plus the anti-PD-1 agent serplulimab significantly extended OS and reduced death risk by 38% in ES-SCLC [15].